Healthcare News

POUR DIFFUSION IMMÉDIATE GENFIT ANNONCE SON INTENTION DE PROCÉDER À UNE OFFRE AU PUBLIC AUX ÉTATS-UNIS Lille (France), Cambridge (Massachusetts, États-Unis), le 19 novembre 2018 - GENFIT SA...

FOR IMMEDIATE RELEASE GENFIT ANNOUNCES PLANS TO CONDUCT REGISTERED PUBLIC OFFERING IN THE UNITED STATES Lille (France), Cambridge (Massachusetts, United States), November 19, 2018 - GENFIT...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} FOR IMMEDIATE RELEASE GENFIT...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} POUR DIFFUSION IMMÉDIATE GENFIT...

サンディエゴ, Nov. 19, 2018 (GLOBE NEWSWIRE) -- 三共株式会社（以下、第一三共社）との継続的なパートナーシップにより、インビボスクライブ社は、第一三共社のキザルチニブ（quizartinib）の日本での承認申請に続き、リューコストラット CDx FLT3 変異検査をキザルチニブのコンパニオン診断薬として日本で承認申請した事をお知らせいたします。 ...

PETALUMA, Calif., Nov. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of a “best efforts” public offering of units consisting of one share of...

BUENA, N.J., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), on November 13, 2018 received a standard notice from NASDAQ stating that, as a result of not having timely filed its...

Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation  Approval...

BRISBANE, Calif., Nov. 16, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...

LYON, Frankreich und CAMBRIDGE, Mass., Nov. 16, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), ein in der klinischen Entwicklungsphase tätiges Biopharma-Unternehmen, das...